US · WST · MEDICAL - INSTRUMENTS & SUPPLIES
West Pharmaceutical Services, Inc. (WST) intrinsic value and stock valuation
$390.30as of 2026-11-21 · Mkt cap 24.92B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
West Pharmaceutical Services, Inc. DCF and intrinsic value
InvestorsCraft values WST with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from WST’s statements →
West Pharmaceutical Services, Inc. Graham Number
Graham Number: $82.15d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Illumina, Inc. (ILMN) $192.82
- Waters Corporation (WAT) $440.45
- Quest Diagnostics Incorporated (DGX) $258.28
- Labcorp Holdings Inc. (LH) $367.13
- Incyte Corporation (INCY) $114.63
- STERIS plc (STE) $255.76
- Zimmer Biomet Holdings, Inc. (ZBH) $101.10
- Medpace Holdings, Inc. (MEDP) $610.54
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B |
| Operating income | $617.4M | $594.6M | $710.9M | $763.5M | $758.7M |
| Net income | $493.7M | $492.7M | $593.4M | $585.9M | $661.8M |
| EPSd | $6.79M | $6.69M | $7.88M | $7.73M | $8.67M |
| Operating cash flow | $754.8M | $653.4M | $776.5M | $724M | $584M |
| Capital expenditure | -$-285.9M | -$-377M | -$-362M | -$-284.6M | -$-253.4M |
| Free cash flow | $468.9M | $276.4M | $414.5M | $439.4M | $330.6M |
| Total assets | $4.27B | $3.64B | $3.83B | $3.62B | $3.31B |
| Total debt | $416.7M | $305.3M | $309M | $317.9M | $325.3M |
| Net debt | -$-374.6M | -$-179.3M | -$-544.9M | -$-576.4M | -$-437.3M |
| Total equity | $3.18B | $2.68B | $2.88B | $2.68B | $2.34B |
| Cash and short-term investments | $791.3M | $484.6M | $853.9M | $894.3M | $762.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B |
| Cost of revenue | $1.97B | $1.89B | $1.82B | $1.75B | $1.66B |
| Gross profit | $1.1B | $1B | $1.13B | $1.14B | $1.17B |
| Research and development expenses | $74.3M | $69.1M | $68.4M | $58.5M | $52.8M |
| Selling, general and administrative expenses | $393.1M | $338.5M | $353.4M | $316.9M | $361.9M |
| Other expenses | $18.5M | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $485.9M | $407.6M | $421.8M | $375.4M | $414.7M |
| Cost and expenses | $2.46B | $2.3B | $2.24B | $2.12B | $2.07B |
| Interest income | $17.7M | $19.6M | $28M | $5.1M | $1M |
| Interest expense | $600K | $2.9M | $8.8M | $7.6M | $8.5M |
| Depreciation and amortization | $124.4M | $155.4M | $137.3M | $120.6M | $122.3M |
| Ebitda | $723.6M | $743.8M | $844.1M | $808.1M | $879.7M |
| Operating income | $617.4M | $594.6M | $710.9M | $763.5M | $758.7M |
| Total other income/expenses, net | -$-2.1M | $5.6M | $4.8M | -$-62.9M | $10.3M |
| Income before tax | $615.3M | $600.2M | $715.7M | $700.6M | $769M |
| Income tax expense | $121.6M | $107.5M | $122.3M | $114.7M | $107.2M |
| Net income | $493.7M | $492.7M | $593.4M | $585.9M | $661.8M |
| Weighted average shares outstanding | $72.3M | $73M | $74.3M | $74.4M | $74.4M |
| Weighted average diluted shares outstanding | $72.7M | $73.7M | $75.3M | $75.8M | $76.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $791.3M | $484.6M | $853.9M | $894.3M | $762.6M |
| Net receivables | $574.4M | $552.5M | $512M | $507.4M | $489M |
| Inventory | $443.9M | $377M | $434.7M | $414.8M | $378.4M |
| Total current assets | $1.98B | $1.54B | $1.94B | $1.92B | $1.74B |
| Property, plant and equipment, net | $1.84B | $1.69B | $1.51B | $1.26B | $1.13B |
| Goodwill and intangible assets | $117.7M | $116.9M | $123.6M | $125.7M | $132.9M |
| Long-term investments | $212.3M | $202.1M | $210M | $204.9M | $207.7M |
| Total non-current assets | $2.29B | $2.11B | $1.89B | $1.7B | $1.57B |
| Total assets | $4.27B | $3.64B | $3.83B | $3.62B | $3.31B |
| Accounts payable | $253.7M | $239.3M | $242.4M | $215.4M | $232.2M |
| Short-term debt | $22.7M | $18.8M | $151.7M | $18.2M | $53.5M |
| Deferred revenue | $0.00 | $49.6M | $41.7M | $57.3M | $48.7M |
| Total current liabilities | $654.9M | $550.4M | $671.8M | $519M | $594.1M |
| Long-term debt | $394M | $286.5M | $157.3M | $299.7M | $271.8M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $439.1M | $410.7M | $276.7M | $412.9M | $384.3M |
| Capital lease obligations | $95.6M | $83.9M | $102.2M | $109M | $72.3M |
| Total liabilities | $1.09B | $961.1M | $948.5M | $931.9M | $978.4M |
| Common stock | $18.8M | $18.8M | $18.8M | $18.8M | $18.8M |
| Retained earnings | $4.37B | $3.96B | $3.52B | $2.99B | $2.46B |
| Accumulated other comprehensive income (loss) | -$-105.5M | -$-258.1M | -$-143.8M | -$-183M | -$-159.6M |
| Total equity | $3.18B | $2.68B | $2.88B | $2.68B | $2.34B |
| Total investments | $212.3M | $202.1M | $210M | $204.9M | $207.7M |
| Total debt | $416.7M | $305.3M | $309M | $317.9M | $325.3M |
| Net debt | -$-374.6M | -$-179.3M | -$-544.9M | -$-576.4M | -$-437.3M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $493.7M | $492.7M | $593.4M | $585.9M | $661.8M |
| Depreciation and amortization | $168.6M | $155.4M | $137.3M | $120.6M | $122.3M |
| Stock-based compensation | $23.8M | $18.7M | $23.3M | $23.7M | $37.5M |
| Change in working capital | $79.8M | $2.9M | -$-20.4M | -$-15M | -$-193.8M |
| Accounts receivable | $6.9M | -$-58.8M | $4M | -$-35.6M | -$-123.5M |
| Inventory | -$-62.8M | $42M | -$-13.5M | -$-49.8M | -$-86.5M |
| Accounts payable | $17.9M | $2.9M | $4.4M | -$-2.8M | $16.8M |
| Net cash provided by operating activities | $754.8M | $653.4M | $776.5M | $724M | $584M |
| Investments in property, plant and equipment | -$-285.9M | -$-377M | -$-362M | -$-284.6M | -$-253.4M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | -$-2.2M |
| Net cash used for investing activities | -$-285.9M | -$-378.7M | -$-368.7M | -$-288.2M | -$-253.1M |
| Common stock issued | $18.2M | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-134M | -$-566.6M | -$-451.2M | -$-222.2M | -$-151.9M |
| Dividends paid | -$-61.2M | -$-59.1M | -$-57M | -$-54.1M | -$-51.1M |
| Net cash used for financing activities | -$-185.1M | -$-622.6M | -$-459.6M | -$-293.6M | -$-168.1M |
| Net change in cash | $306.7M | -$-369.3M | -$-40.4M | $131.7M | $147.1M |
| Cash at end of period | $791.3M | $484.6M | $853.9M | $894.3M | $762.6M |
| Operating cash flow | $754.8M | $653.4M | $776.5M | $724M | $584M |
| Capital expenditure | -$-285.9M | -$-377M | -$-362M | -$-284.6M | -$-253.4M |
| Free cash flow | $468.9M | $276.4M | $414.5M | $439.4M | $330.6M |
Line items
Line items
Line items
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
- CEO
- Eric Green
- Employees
- 10.8K
- Beta
- 1.16
Included in
Explore
Frequently asked questions
What is the intrinsic value of West Pharmaceutical Services, Inc. (WST)?
West Pharmaceutical Services, Inc. (WST) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is WST undervalued?
WST trades at a price of $390.30 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.